What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by #Rh

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by #RheumNow & its Faculty.
      RT @drdavidliew: My video take from yesterday for @RheumNow:
      'Tired of Doing Nothing About Fatigue' #ACR21
      https://t.co/

      David Liew drdavidliew

      4 years ago
      My video take from yesterday for @RheumNow: 'Tired of Doing Nothing About Fatigue' #ACR21 https://t.co/EXjOibL5s9 https://t.co/cR6r8GdDor
      RT @swethaann23: AxSpA pts who achieve ASDAS low disease activity (LDA) 6 mo after bDMARD initiation

      ⭐️ 25% achiev

      swethaann23 swethaann23

      4 years ago
      AxSpA pts who achieve ASDAS low disease activity (LDA) 6 mo after bDMARD initiation ⭐️ 25% achieved ASDAS LDA ⭐️ASDAS LDA achievers were ♂️ + naïve to c/b DMARDs + with PROM / Clinical improvement ⭐️ASDAS LDA non-achievers=depression, uveitis, IBD Abst# 0925 #ACR21 @RheumNow
      RT @uptoTate: Turkish study finds that ETN may be negatively associated w/ the development of ADA in AS pts. Abs 0936 #A

      Dr. Rachel Tate uptoTate

      4 years ago
      Turkish study finds that ETN may be negatively associated w/ the development of ADA in AS pts. Abs 0936 #ACR21 #RheumNow @RheumNow https://t.co/z3pYDpp1NN https://t.co/MR1R41rCHV
      RT @RHEUMarampa: They're VITAL!🤓 Prof @karen_kc123 presents the results of the RCT (huge population size) showing how

      sheila RHEUMarampa

      4 years ago
      They're VITAL!🤓 Prof @karen_kc123 presents the results of the RCT (huge population size) showing how 5-yr supplementation with Vit D3 &/or n-3 fatty acids ⬇incident autoimmune dse vs. non-takers. Game changing?! @RheumNow #ACR21 #ACRBest abs0957 https://t.co/X9QaB1B5Ac
      RT @synovialjoints: PsA impacts many aspects of life. PRO such as VAS pain
      and HAQ, are commonly assessed. The FACIT-Fat

      Dr. Antoni Chan synovialjoints

      4 years ago
      PsA impacts many aspects of life. PRO such as VAS pain and HAQ, are commonly assessed. The FACIT-Fatigue scale, ranked the highest by patients. Personalized discussion is vital in assessment and shared decision making @RheumNow #ACR21 Abst#0751 https://t.co/gRfYK4sHc6 https://t.co/f5xjUnXsGQ
      RT @swethaann23: Evaluate effectiveness and Rx survival of different TNFI in cohort of axSpA

      ⭐️No difference among

      swethaann23 swethaann23

      4 years ago
      Evaluate effectiveness and Rx survival of different TNFI in cohort of axSpA ⭐️No difference among different TNFI ⭐️No difference between nr-axSpA and AS ⭐️Failure to initial TNFI did not diminish effectiveness or drug survival of subsequent TNFi Rx Abst#0938 #ACR21 @RheumNow
      RT @ericdeinmd: #ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts
      ⭐️TNFi use ⬆️ disease activity vs ABA in obese

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts ⭐️TNFi use ⬆️ disease activity vs ABA in obese pts ⭐️TNFi use ⬆️ activity vs TCZ in non-obese pts ⭐️No diff w RTX, Tofa ▶️Further research needed: Wt-based dosing? SC vs IV? https://t.co/K8WycPTgxW @Rheumnow #ACRBest
      RT @DrPetryna: Abst0897 #ACR21 @RheumNow radiographic progression in AS accelerates w/age, highest at age 30–39 (mean

      Olga Petryna DrPetryna

      4 years ago
      Abst0897 #ACR21 @RheumNow radiographic progression in AS accelerates w/age, highest at age 30–39 (mean mSASSS change per year 1.148), followed by 40–49 , 20–29,≥50 & least < 20 (0.643). radiographic damage rapidly ⬆️ among 20s w/risk factors:⬆️ CRP &preexisting syndesmophytes https://t.co/tiAgKUyjJq
      RT @drdavidliew: ORAL Surveillance MACE conclusions:
      So this is fair: tofacitinib acts as a CV risk factor, there are ma

      David Liew drdavidliew

      4 years ago
      ORAL Surveillance MACE conclusions: So this is fair: tofacitinib acts as a CV risk factor, there are many others, we need to address CV risk in RA pts. Nevertheless, in terms of MI risk, tofa vs TNFi, if I had one CV risk factor, I know what I'd do. #ACR21 ABST0958 @RheumNow https://t.co/4Z79XtTzl9
      RT @drdavidliew: For what it's worth, I'm struck by my conversation last week with one RA patient in clinic with stents.

      David Liew drdavidliew

      4 years ago
      For what it's worth, I'm struck by my conversation last week with one RA patient in clinic with stents. 3y ago post-MTX/HCQ had asked for a JAKi first line, immaculate RA response. Listened, no blinking, okay thanks doctor - I'm happy where I am. Next question. #ACR21 @RheumNow
      RT @drdavidliew: “For many patients, it doesn’t matter if there’s an increased risk, because they don’t want to

      David Liew drdavidliew

      4 years ago
      “For many patients, it doesn’t matter if there’s an increased risk, because they don’t want to go to the alternative” - Christina Charles-Schoeman, presenting ORAL Surveillance MACE data in the #ACR21 plenary Discussions with pts needed, these data justify that need. @RheumNow
      RT @uptoTate: SELECT-AXIS 1: UPA 15 mg QD consistently efficacious over 2 years for ASAS40. Low radiographic progression

      Dr. Rachel Tate uptoTate

      4 years ago
      SELECT-AXIS 1: UPA 15 mg QD consistently efficacious over 2 years for ASAS40. Low radiographic progression rates in AS pts. No new safety findings were observed. Abs 0924 #ACR21 #RheumNow @RheumNow https://t.co/CWvH1OPGyR https://t.co/uC67fJZDCE
      RT @DrPetryna: Abst0509 #ACR21 @RheumNow study of plasma concentrations of Deucravacitinib show high functional selectiv

      Olga Petryna DrPetryna

      4 years ago
      Abst0509 #ACR21 @RheumNow study of plasma concentrations of Deucravacitinib show high functional selectivity for TYK2 while Tofa, Upa & Bari inhibit JAK1/2/3 to varying degrees show no meaningful inhibition of TYK2. Distinct class of kinase inhibitor as compared to JAKs
      RT @uptoTate: SELECT-AXIS 1 Post Hoc Analysis results showed improvement in PROs &amp; reduction in back pain score at 1

      Dr. Rachel Tate uptoTate

      4 years ago
      SELECT-AXIS 1 Post Hoc Analysis results showed improvement in PROs & reduction in back pain score at 12 weeks predicted clinical outcomes at 1 year in AS pts. Abs 0926 #ACR21 #RheumNow @RheumNow https://t.co/vRVpv1O6YS https://t.co/wjafMf1UPY

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×